Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder
Evaluate the effect of paliperidone palmitate once-monthly (PP1M) injectable on the specific functioning domains of the Personal and Social Performance (PSP) scale in patients with schizoaffective disorder (SCA) participating in a long-term study. This study (NCT01193153) included both in- and outpa...
Saved in:
| Published in | Schizophrenia research Vol. 192; pp. 185 - 193 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.02.2018
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0920-9964 1573-2509 1573-2509 |
| DOI | 10.1016/j.schres.2017.04.004 |
Cover
| Abstract | Evaluate the effect of paliperidone palmitate once-monthly (PP1M) injectable on the specific functioning domains of the Personal and Social Performance (PSP) scale in patients with schizoaffective disorder (SCA) participating in a long-term study.
This study (NCT01193153) included both in- and outpatient subjects with SCA experiencing an acute exacerbation of psychotic and mood symptoms. Subjects were treated with PP1M either as monotherapy or in combination with antidepressants or mood stabilizers during a 25-week open-label (OL) phase. Stabilized subjects were randomly assigned 1:1 (PP1M or placebo) into a 15-month double-blind (DB) relapse-prevention period. Functioning of the randomized subjects during OL and DB phases was evaluated using the PSP scale (four domains: socially useful activities, personal/social relationships, self-care, and disturbing/aggressive behaviors). Three statistical approaches were utilized to analyze PSP scores to assess robustness and consistency of findings. No adjustments were made for multiplicity.
334 of 667 enrolled subjects were stabilized with PP1M, randomly assigned to PP1M (n=164) or placebo (n=170) in the DB phase, and included in this analysis. Improvements in all PSP domain scores were observed during the OL phase and were maintained during the DB phase with PP1M, but decreased with placebo. Differences compared to placebo were significant in all four PSP domains during the DB phase (P≤0.008).
The analysis in this study showed that PP1M improves functioning, as measured by the four PSP domain scores, in symptomatic subjects with SCA. Functioning was maintained compared with placebo. |
|---|---|
| AbstractList | Evaluate the effect of paliperidone palmitate once-monthly (PP1M) injectable on the specific functioning domains of the Personal and Social Performance (PSP) scale in patients with schizoaffective disorder (SCA) participating in a long-term study.
This study (NCT01193153) included both in- and outpatient subjects with SCA experiencing an acute exacerbation of psychotic and mood symptoms. Subjects were treated with PP1M either as monotherapy or in combination with antidepressants or mood stabilizers during a 25-week open-label (OL) phase. Stabilized subjects were randomly assigned 1:1 (PP1M or placebo) into a 15-month double-blind (DB) relapse-prevention period. Functioning of the randomized subjects during OL and DB phases was evaluated using the PSP scale (four domains: socially useful activities, personal/social relationships, self-care, and disturbing/aggressive behaviors). Three statistical approaches were utilized to analyze PSP scores to assess robustness and consistency of findings. No adjustments were made for multiplicity.
334 of 667 enrolled subjects were stabilized with PP1M, randomly assigned to PP1M (n=164) or placebo (n=170) in the DB phase, and included in this analysis. Improvements in all PSP domain scores were observed during the OL phase and were maintained during the DB phase with PP1M, but decreased with placebo. Differences compared to placebo were significant in all four PSP domains during the DB phase (P≤0.008).
The analysis in this study showed that PP1M improves functioning, as measured by the four PSP domain scores, in symptomatic subjects with SCA. Functioning was maintained compared with placebo. Abstract Objective Evaluate the effect of paliperidone palmitate once-monthly (PP1M) injectable on the specific functioning domains of the Personal and Social Performance (PSP) scale in patients with schizoaffective disorder (SCA) participating in a long-term study. Methods This study ( NCT01193153 ) included both in- and outpatient subjects with SCA experiencing an acute exacerbation of psychotic and mood symptoms. Subjects were treated with PP1M either as monotherapy or in combination with antidepressants or mood stabilizers during a 25-week open-label (OL) phase. Stabilized subjects were randomly assigned 1:1 (PP1M or placebo) into a 15-month double-blind (DB) relapse-prevention period. Functioning of the randomized subjects during OL and DB phases was evaluated using the PSP scale (four domains: socially useful activities, personal/social relationships, self-care, and disturbing/aggressive behaviors). Three statistical approaches were utilized to analyze PSP scores to assess robustness and consistency of findings. No adjustments were made for multiplicity. Results 334 of 667 enrolled subjects were stabilized with PP1M, randomly assigned to PP1M ( n = 164) or placebo ( n = 170) in the DB phase, and included in this analysis. Improvements in all PSP domain scores were observed during the OL phase and were maintained during the DB phase with PP1M, but decreased with placebo. Differences compared to placebo were significant in all four PSP domains during the DB phase ( P ≤ 0.008). Conclusion The analysis in this study showed that PP1M improves functioning, as measured by the four PSP domain scores, in symptomatic subjects with SCA. Functioning was maintained compared with placebo. Evaluate the effect of paliperidone palmitate once-monthly (PP1M) injectable on the specific functioning domains of the Personal and Social Performance (PSP) scale in patients with schizoaffective disorder (SCA) participating in a long-term study.OBJECTIVEEvaluate the effect of paliperidone palmitate once-monthly (PP1M) injectable on the specific functioning domains of the Personal and Social Performance (PSP) scale in patients with schizoaffective disorder (SCA) participating in a long-term study.This study (NCT01193153) included both in- and outpatient subjects with SCA experiencing an acute exacerbation of psychotic and mood symptoms. Subjects were treated with PP1M either as monotherapy or in combination with antidepressants or mood stabilizers during a 25-week open-label (OL) phase. Stabilized subjects were randomly assigned 1:1 (PP1M or placebo) into a 15-month double-blind (DB) relapse-prevention period. Functioning of the randomized subjects during OL and DB phases was evaluated using the PSP scale (four domains: socially useful activities, personal/social relationships, self-care, and disturbing/aggressive behaviors). Three statistical approaches were utilized to analyze PSP scores to assess robustness and consistency of findings. No adjustments were made for multiplicity.METHODSThis study (NCT01193153) included both in- and outpatient subjects with SCA experiencing an acute exacerbation of psychotic and mood symptoms. Subjects were treated with PP1M either as monotherapy or in combination with antidepressants or mood stabilizers during a 25-week open-label (OL) phase. Stabilized subjects were randomly assigned 1:1 (PP1M or placebo) into a 15-month double-blind (DB) relapse-prevention period. Functioning of the randomized subjects during OL and DB phases was evaluated using the PSP scale (four domains: socially useful activities, personal/social relationships, self-care, and disturbing/aggressive behaviors). Three statistical approaches were utilized to analyze PSP scores to assess robustness and consistency of findings. No adjustments were made for multiplicity.334 of 667 enrolled subjects were stabilized with PP1M, randomly assigned to PP1M (n=164) or placebo (n=170) in the DB phase, and included in this analysis. Improvements in all PSP domain scores were observed during the OL phase and were maintained during the DB phase with PP1M, but decreased with placebo. Differences compared to placebo were significant in all four PSP domains during the DB phase (P≤0.008).RESULTS334 of 667 enrolled subjects were stabilized with PP1M, randomly assigned to PP1M (n=164) or placebo (n=170) in the DB phase, and included in this analysis. Improvements in all PSP domain scores were observed during the OL phase and were maintained during the DB phase with PP1M, but decreased with placebo. Differences compared to placebo were significant in all four PSP domains during the DB phase (P≤0.008).The analysis in this study showed that PP1M improves functioning, as measured by the four PSP domain scores, in symptomatic subjects with SCA. Functioning was maintained compared with placebo.CONCLUSIONThe analysis in this study showed that PP1M improves functioning, as measured by the four PSP domain scores, in symptomatic subjects with SCA. Functioning was maintained compared with placebo. |
| Author | Fu, Dong-Jing Schooler, Nina R. Lindenmayer, Jean-Pierre Walling, David Turkoz, Ibrahim Alphs, Larry |
| Author_xml | – sequence: 1 givenname: Dong-Jing surname: Fu fullname: Fu, Dong-Jing email: dfu@its.jnj.com organization: Janssen Research & Development, LLC, Titusville, NJ 08560, USA – sequence: 2 givenname: Ibrahim surname: Turkoz fullname: Turkoz, Ibrahim organization: Janssen Research & Development, LLC, Titusville, NJ 08560, USA – sequence: 3 givenname: David orcidid: 0000-0001-8638-2086 surname: Walling fullname: Walling, David organization: Collaborative Neuroscience Network, Inc, Garden Grove, CA, USA – sequence: 4 givenname: Jean-Pierre surname: Lindenmayer fullname: Lindenmayer, Jean-Pierre organization: New York University, New York, NY, USA – sequence: 5 givenname: Nina R. surname: Schooler fullname: Schooler, Nina R. organization: SUNY Downstate Medical Center, Brooklyn, NY, USA – sequence: 6 givenname: Larry orcidid: 0000-0001-9991-6905 surname: Alphs fullname: Alphs, Larry organization: Janssen Scientific Affairs, LLC, Titusville, NJ, 08560, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28454922$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVktGK1DAUhoOsuLOrbyCSS286nrRNpxURZHFVWHBh9TqcpqdOxjapSToyvtu-m6mzeiHI4kVIOPnPH87_5YydWGeJsacC1gJE9WK3DnrrKaxzEJs1lGuA8gFbCbkpslxCc8JW0OSQNU1VnrKzEHYAICRsHrHTvC5l2eT5it1e42Am8qZL7nzCYTQRI3FnNWWjs3E7HPiIxsa0Ajfj5N2eRrKRG8v72eponDX2C-_c-Evieh63xK_JB2dx4Gg7fuO0ScdU650fMXnzoHEgrt04oaeOfzdxy6cBNbVucQ5zuyMdw_EiTWp-OOz7VDJ74p0JznfkH7OHPQ6Bntzt5-zz5dtPF--zq4_vPly8ucq0FFXMWqQSEYs2z6FHXUsSUJe9lEJXsiqKqiBqNm3bNwgo6rYpC411S7nsNEArinP2_Oibpv82U4hqNEHTMKAlNwcl6qZIbiBlkj67k87tSJ2avBnRH9TvyJOgPAq0dyF46v9IBKiFrNqpI1m1kFVQqkQ2tb38q00vpFL40aMZ7mt-fWymFNLekE8iQwlDZ3yKVHXO_K-BHow1ieFXOlDYudkn1ikIFXIF6mb5ecvHE5sCRCOKZPDq3wb3v_8TElrw5A |
| CitedBy_id | crossref_primary_10_3389_fpsyt_2020_529672 crossref_primary_10_1017_S1092852919001226 crossref_primary_10_1007_s40261_018_0734_1 crossref_primary_10_7759_cureus_65939 crossref_primary_10_1002_14651858_CD008016_pub3 crossref_primary_10_1080_02688697_2019_1668539 crossref_primary_10_1186_s12888_020_02488_1 crossref_primary_10_1007_s11920_019_1114_0 crossref_primary_10_1016_j_jpsychires_2020_06_013 crossref_primary_10_1002_hup_2658 crossref_primary_10_1080_14656566_2021_2023496 crossref_primary_10_1016_j_schres_2020_11_040 crossref_primary_10_1186_s12888_021_03513_7 |
| Cites_doi | 10.1016/j.pnpbp.2003.09.024 10.1185/03007991003798927 10.1517/14656566.2016.1161029 10.1007/s40265-016-0551-x 10.1586/17512433.2016.1121809 10.2147/NDT.S12612 10.1517/14656566.2015.1114100 10.4088/JCP.08m04221 10.1097/YIC.0000000000000038 10.1007/s40258-014-0095-8 10.1111/j.1600-0447.2000.tb10933.x 10.2147/NDT.S15911 10.1016/j.schres.2011.08.024 10.4088/JCP.14m09416 10.1176/appi.ps.53.1.94 10.1016/j.schres.2013.04.026 10.1016/j.psychres.2007.11.012 10.1097/JCP.0b013e3181dd3103 10.1016/j.pnpbp.2010.11.008 10.1007/s40263-016-0350-7 |
| ContentType | Journal Article |
| Copyright | 2017 The Authors The Authors Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2017 The Authors – notice: The Authors – notice: Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 |
| DOI | 10.1016/j.schres.2017.04.004 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1573-2509 |
| EndPage | 193 |
| ExternalDocumentID | 28454922 10_1016_j_schres_2017_04_004 S0920996417301913 1_s2_0_S0920996417301913 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M -~X .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 4H- 53G 5VS 7-5 71M 8P~ 9JM 9JO AABNK AADFP AAEDT AAEDW AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABIVO ABJNI ABMAC ABMZM ABOYX ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACIUM ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEG HMK HMO HMQ HMW HVGLF HZ~ IHE J1W KOM M29 M2V M39 M3V M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPS SSB SSH SSN SSY SSZ T5K WUQ Z5R ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG 6I. AADPK AAFTH AAIAV ABLVK ABYKQ AFYLN AJBFU EFLBG LCYCR AAYXX AGRNS CITATION NPM 7X8 ACLOT ~HD |
| ID | FETCH-LOGICAL-c516t-bae4aaa3b220fac85e1084f551c6563363ee97bbf9a0a18b943ca8be25dc00b13 |
| IEDL.DBID | AIKHN |
| ISSN | 0920-9964 1573-2509 |
| IngestDate | Sun Sep 28 10:54:25 EDT 2025 Wed Feb 19 02:42:57 EST 2025 Thu Apr 24 23:06:07 EDT 2025 Tue Jul 01 04:00:54 EDT 2025 Fri Feb 23 02:45:53 EST 2024 Tue Feb 25 20:03:40 EST 2025 Tue Aug 26 19:42:05 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Long-acting injectable Schizoaffective Paliperidone palmitate Long term Personal and Social Performance scale Functioning |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c516t-bae4aaa3b220fac85e1084f551c6563363ee97bbf9a0a18b943ca8be25dc00b13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0001-8638-2086 0000-0001-9991-6905 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0920996417301913 |
| PMID | 28454922 |
| PQID | 1893551055 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1893551055 pubmed_primary_28454922 crossref_primary_10_1016_j_schres_2017_04_004 crossref_citationtrail_10_1016_j_schres_2017_04_004 elsevier_sciencedirect_doi_10_1016_j_schres_2017_04_004 elsevier_clinicalkeyesjournals_1_s2_0_S0920996417301913 elsevier_clinicalkey_doi_10_1016_j_schres_2017_04_004 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-02-01 |
| PublicationDateYYYYMMDD | 2018-02-01 |
| PublicationDate_xml | – month: 02 year: 2018 text: 2018-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Schizophrenia research |
| PublicationTitleAlternate | Schizophr Res |
| PublicationYear | 2018 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Lindenmayer, Liu-Seifert, Kulkarni, Kinon, Stauffer, Edwards, Chen, Adams, Ascher-Svanum, Buckley, Citrome, Volavka (bb0075) 2009; 70 Alphs, Fu, Turkoz (bb0005) 2016; 17 Lerner, Libov, Kotler, Strous (bb0065) 2004; 28 Burns, Patrick (bb0025) 2007; 116 Nicholl, Nasrallah, Nuamah, Akhras, Gagnon, Gopal (bb0115) 2010; 26 Canuso, Turkoz, Fu, Bossie (bb0030) 2010; 6 Marneros, Deister, Rohde (bb0085) 1990; 82 Malaspina, Owen, Heckers, Tandon, Bustillo, Schultz, Barch, Gaebel, Gur, Tsuang, van Os, Carpenter (bb0080) 2013; 150 Nasrallah, Morosini, Gagnon (bb0110) 2008; 161 American Psychiatric Association (bb0010) 2013 Flynn, Grieger, Benedek (bb0045) 2002; 53 Citrome (bb0035) 2016; 9 Morosini, Magliano, Brambilla, Ugolini, Pioli (bb0100) 2000; 101 McDonnell, Landry, Detke (bb0090) 2014; 29 Verbeke, Molenberghs (bb0140) 2000 Janssen Pharmaceuticals, Inc. (bb0055) 2014 Boden, Brandt, Kieler, Andersen, Reutfors (bb0020) 2011; 133 McElroy, Keck, Strakowski (bb0095) 1999; 60 Pandina, Lindenmayer, Lull, Lim, Gopal, Herben, Kusumakar, Yuen, Palumbo (bb0125) 2010; 30 Potkin, Preda (bb0135) 2016; 17 Nasrallah, Goldberg, Correll, SAD Working Group (bb0105) 2010; 22 Pandina, Lane, Gopal, Gassmann-Mayer, Hough, Remmerie, Simpson (bb0120) 2011; 35 Fu, Turkoz, Simonson, Walling, Schooler, Lindenmayer, Canuso, Alphs (bb0050) 2015; 76 Williams, Chandrasena, Beauclair, Luong, Lam (bb0145) 2014; 10 Karve, Markowitz, Fu, Lindenmayer, Wang, Candrilli, Alphs (bb0060) 2014; 12 Apiquian, Cordoba, Louza (bb0015) 2010; 7 Lindenmayer, Kaur (bb0070) 2016; 76 Diggle, Heagerty, Liang, Zeger (bb0040) 2002 Parellada, Bioque (bb0130) 2016; 30 Citrome (10.1016/j.schres.2017.04.004_bb0035) 2016; 9 Lindenmayer (10.1016/j.schres.2017.04.004_bb0070) 2016; 76 Flynn (10.1016/j.schres.2017.04.004_bb0045) 2002; 53 American Psychiatric Association (10.1016/j.schres.2017.04.004_bb0010) 2013 Malaspina (10.1016/j.schres.2017.04.004_bb0080) 2013; 150 Potkin (10.1016/j.schres.2017.04.004_bb0135) 2016; 17 Diggle (10.1016/j.schres.2017.04.004_bb0040) 2002 Karve (10.1016/j.schres.2017.04.004_bb0060) 2014; 12 Apiquian (10.1016/j.schres.2017.04.004_bb0015) 2010; 7 Williams (10.1016/j.schres.2017.04.004_bb0145) 2014; 10 Lindenmayer (10.1016/j.schres.2017.04.004_bb0075) 2009; 70 Fu (10.1016/j.schres.2017.04.004_bb0050) 2015; 76 McElroy (10.1016/j.schres.2017.04.004_bb0095) 1999; 60 Morosini (10.1016/j.schres.2017.04.004_bb0100) 2000; 101 Nasrallah (10.1016/j.schres.2017.04.004_bb0105) 2010; 22 Pandina (10.1016/j.schres.2017.04.004_bb0120) 2011; 35 Marneros (10.1016/j.schres.2017.04.004_bb0085) 1990; 82 Boden (10.1016/j.schres.2017.04.004_bb0020) 2011; 133 Lerner (10.1016/j.schres.2017.04.004_bb0065) 2004; 28 McDonnell (10.1016/j.schres.2017.04.004_bb0090) 2014; 29 Alphs (10.1016/j.schres.2017.04.004_bb0005) 2016; 17 Nasrallah (10.1016/j.schres.2017.04.004_bb0110) 2008; 161 Parellada (10.1016/j.schres.2017.04.004_bb0130) 2016; 30 Pandina (10.1016/j.schres.2017.04.004_bb0125) 2010; 30 Nicholl (10.1016/j.schres.2017.04.004_bb0115) 2010; 26 Burns (10.1016/j.schres.2017.04.004_bb0025) 2007; 116 Janssen Pharmaceuticals, Inc. (10.1016/j.schres.2017.04.004_bb0055) 2014 Verbeke (10.1016/j.schres.2017.04.004_bb0140) 2000 Canuso (10.1016/j.schres.2017.04.004_bb0030) 2010; 6 |
| References_xml | – volume: 28 start-page: 89 year: 2004 end-page: 98 ident: bb0065 article-title: Combination of “atypical” antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder publication-title: Prog. Neuro-Psychopharmacol. Biol. Psychiatry – volume: 116 start-page: 403 year: 2007 end-page: 418 ident: bb0025 article-title: Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr publication-title: Scandinavica – year: 2002 ident: bb0040 article-title: Analysis of Longitudinal Data – volume: 22 start-page: S1 year: 2010 end-page: 12 ident: bb0105 article-title: Differential diagnosis and therapeutic management of schizoaffective disorder publication-title: Ann. Clin. Psychiatry – volume: 26 start-page: 1471 year: 2010 end-page: 1484 ident: bb0115 article-title: Personal and social function in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention publication-title: Curr. Med. Res. Opin. – volume: 29 start-page: 322 year: 2014 end-page: 331 ident: bb0090 article-title: Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study publication-title: Int. Clin. Psychopharmacol. – volume: 101 start-page: 323 year: 2000 end-page: 329 ident: bb0100 article-title: Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning publication-title: Acta Psychiatr. Scand. – volume: 9 start-page: 169 year: 2016 end-page: 186 ident: bb0035 article-title: Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil publication-title: Expert. Rev. Clin. Pharmacol. – volume: 82 start-page: 352 year: 1990 end-page: 358 ident: bb0085 article-title: Psychopathological and social status of patients with affective, schizophrenic and schizoaffective disorders after long-term course. Acta Psychiatr publication-title: Scand. – year: 2000 ident: bb0140 article-title: Linear Mixed Models for Longitudinal Data – volume: 53 start-page: 94 year: 2002 end-page: 96 ident: bb0045 article-title: Pharmacologic treatment of hospitalized patients with schizoaffective disorder publication-title: Psychiatr. Serv. – volume: 7 start-page: 19 year: 2010 end-page: 26 ident: bb0015 article-title: Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America publication-title: Neuropsychiatr. Dis. Treat. – volume: 76 start-page: 253 year: 2015 end-page: 262 ident: bb0050 article-title: Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder publication-title: J. Clin. Psychiatry – volume: 133 start-page: 36 year: 2011 end-page: 41 ident: bb0020 article-title: Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder publication-title: Schizophr. Res. – volume: 76 start-page: 589 year: 2016 end-page: 604 ident: bb0070 article-title: Antipsychotic management of schizoaffective disorder: a review publication-title: Drugs – volume: 30 start-page: 235 year: 2010 end-page: 244 ident: bb0125 article-title: A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia publication-title: J. Clin. Psychopharmacol. – volume: 17 start-page: 871 year: 2016 end-page: 883 ident: bb0005 article-title: Paliperidone for the treatment of schizoaffective disorder publication-title: Expert. Opin. Pharmacother. – volume: 10 start-page: 417 year: 2014 end-page: 425 ident: bb0145 article-title: Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada publication-title: Neuropsychiatr. Dis. Treat. – volume: 70 start-page: 990 year: 2009 end-page: 996 ident: bb0075 article-title: Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response publication-title: J. Clin. Psychiatry – volume: 12 start-page: 335 year: 2014 end-page: 346 ident: bb0060 article-title: Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder publication-title: Appl. Health Econ. Health Policy – volume: 17 start-page: 395 year: 2016 end-page: 407 ident: bb0135 article-title: Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia publication-title: Expert. Opin. Pharmacother. – volume: 150 start-page: 21 year: 2013 end-page: 25 ident: bb0080 article-title: Schizoaffective disorder in the DSM-5 publication-title: Schizophr. Res. – volume: 35 start-page: 218 year: 2011 end-page: 226 ident: bb0120 article-title: A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia publication-title: Prog. Neuro-Psychopharmacol. Biol. Psychiatry – year: 2013 ident: bb0010 article-title: Diagnostic and Statistical Manual of Mental Disorders – volume: 161 start-page: 213 year: 2008 end-page: 224 ident: bb0110 article-title: Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia publication-title: Psychiatry Res. – volume: 6 start-page: 667 year: 2010 end-page: 679 ident: bb0030 article-title: Role of paliperidone extended-release in treatment of schizoaffective disorder publication-title: Neuropsychiatr. Dis. Treat. – year: 2014 ident: bb0055 article-title: Invega Sustenna (paliperidone palmitate) extended-release injectable suspension, for intramuscular use [package insert] – volume: 30 start-page: 689 year: 2016 end-page: 701 ident: bb0130 article-title: Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia publication-title: CNS Drugs – volume: 60 start-page: 16 year: 1999 end-page: 21 ident: bb0095 article-title: An overview of the treatment of schizoaffective disorder publication-title: J. Clin. Psychiatry – year: 2000 ident: 10.1016/j.schres.2017.04.004_bb0140 – volume: 28 start-page: 89 issue: 1 year: 2004 ident: 10.1016/j.schres.2017.04.004_bb0065 article-title: Combination of “atypical” antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder publication-title: Prog. Neuro-Psychopharmacol. Biol. Psychiatry doi: 10.1016/j.pnpbp.2003.09.024 – year: 2002 ident: 10.1016/j.schres.2017.04.004_bb0040 – volume: 22 start-page: S1 issue: 4 suppl 1 year: 2010 ident: 10.1016/j.schres.2017.04.004_bb0105 article-title: Differential diagnosis and therapeutic management of schizoaffective disorder publication-title: Ann. Clin. Psychiatry – volume: 26 start-page: 1471 issue: 6 year: 2010 ident: 10.1016/j.schres.2017.04.004_bb0115 article-title: Personal and social function in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention publication-title: Curr. Med. Res. Opin. doi: 10.1185/03007991003798927 – volume: 17 start-page: 871 issue: 6 year: 2016 ident: 10.1016/j.schres.2017.04.004_bb0005 article-title: Paliperidone for the treatment of schizoaffective disorder publication-title: Expert. Opin. Pharmacother. doi: 10.1517/14656566.2016.1161029 – volume: 116 start-page: 403 issue: 6 year: 2007 ident: 10.1016/j.schres.2017.04.004_bb0025 article-title: Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr publication-title: Scandinavica – volume: 76 start-page: 589 issue: 5 year: 2016 ident: 10.1016/j.schres.2017.04.004_bb0070 article-title: Antipsychotic management of schizoaffective disorder: a review publication-title: Drugs doi: 10.1007/s40265-016-0551-x – volume: 10 start-page: 417 year: 2014 ident: 10.1016/j.schres.2017.04.004_bb0145 article-title: Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada publication-title: Neuropsychiatr. Dis. Treat. – year: 2013 ident: 10.1016/j.schres.2017.04.004_bb0010 – volume: 9 start-page: 169 issue: 2 year: 2016 ident: 10.1016/j.schres.2017.04.004_bb0035 article-title: Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil publication-title: Expert. Rev. Clin. Pharmacol. doi: 10.1586/17512433.2016.1121809 – volume: 6 start-page: 667 year: 2010 ident: 10.1016/j.schres.2017.04.004_bb0030 article-title: Role of paliperidone extended-release in treatment of schizoaffective disorder publication-title: Neuropsychiatr. Dis. Treat. doi: 10.2147/NDT.S12612 – volume: 17 start-page: 395 issue: 3 year: 2016 ident: 10.1016/j.schres.2017.04.004_bb0135 article-title: Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia publication-title: Expert. Opin. Pharmacother. doi: 10.1517/14656566.2015.1114100 – volume: 70 start-page: 990 issue: 7 year: 2009 ident: 10.1016/j.schres.2017.04.004_bb0075 article-title: Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response publication-title: J. Clin. Psychiatry doi: 10.4088/JCP.08m04221 – volume: 29 start-page: 322 issue: 6 year: 2014 ident: 10.1016/j.schres.2017.04.004_bb0090 article-title: Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study publication-title: Int. Clin. Psychopharmacol. doi: 10.1097/YIC.0000000000000038 – volume: 12 start-page: 335 issue: 3 year: 2014 ident: 10.1016/j.schres.2017.04.004_bb0060 article-title: Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder publication-title: Appl. Health Econ. Health Policy doi: 10.1007/s40258-014-0095-8 – volume: 101 start-page: 323 issue: 4 year: 2000 ident: 10.1016/j.schres.2017.04.004_bb0100 article-title: Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning publication-title: Acta Psychiatr. Scand. doi: 10.1111/j.1600-0447.2000.tb10933.x – volume: 82 start-page: 352 issue: 5 year: 1990 ident: 10.1016/j.schres.2017.04.004_bb0085 article-title: Psychopathological and social status of patients with affective, schizophrenic and schizoaffective disorders after long-term course. Acta Psychiatr publication-title: Scand. – volume: 7 start-page: 19 year: 2010 ident: 10.1016/j.schres.2017.04.004_bb0015 article-title: Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America publication-title: Neuropsychiatr. Dis. Treat. doi: 10.2147/NDT.S15911 – year: 2014 ident: 10.1016/j.schres.2017.04.004_bb0055 – volume: 133 start-page: 36 issue: 1–3 year: 2011 ident: 10.1016/j.schres.2017.04.004_bb0020 article-title: Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder publication-title: Schizophr. Res. doi: 10.1016/j.schres.2011.08.024 – volume: 60 start-page: 16 issue: Suppl. 5 year: 1999 ident: 10.1016/j.schres.2017.04.004_bb0095 article-title: An overview of the treatment of schizoaffective disorder publication-title: J. Clin. Psychiatry – volume: 76 start-page: 253 issue: 3 year: 2015 ident: 10.1016/j.schres.2017.04.004_bb0050 article-title: Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder publication-title: J. Clin. Psychiatry doi: 10.4088/JCP.14m09416 – volume: 53 start-page: 94 issue: 1 year: 2002 ident: 10.1016/j.schres.2017.04.004_bb0045 article-title: Pharmacologic treatment of hospitalized patients with schizoaffective disorder publication-title: Psychiatr. Serv. doi: 10.1176/appi.ps.53.1.94 – volume: 150 start-page: 21 issue: 1 year: 2013 ident: 10.1016/j.schres.2017.04.004_bb0080 article-title: Schizoaffective disorder in the DSM-5 publication-title: Schizophr. Res. doi: 10.1016/j.schres.2013.04.026 – volume: 161 start-page: 213 issue: 2 year: 2008 ident: 10.1016/j.schres.2017.04.004_bb0110 article-title: Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia publication-title: Psychiatry Res. doi: 10.1016/j.psychres.2007.11.012 – volume: 30 start-page: 235 issue: 3 year: 2010 ident: 10.1016/j.schres.2017.04.004_bb0125 article-title: A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia publication-title: J. Clin. Psychopharmacol. doi: 10.1097/JCP.0b013e3181dd3103 – volume: 35 start-page: 218 issue: 1 year: 2011 ident: 10.1016/j.schres.2017.04.004_bb0120 article-title: A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia publication-title: Prog. Neuro-Psychopharmacol. Biol. Psychiatry doi: 10.1016/j.pnpbp.2010.11.008 – volume: 30 start-page: 689 issue: 8 year: 2016 ident: 10.1016/j.schres.2017.04.004_bb0130 article-title: Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia publication-title: CNS Drugs doi: 10.1007/s40263-016-0350-7 |
| SSID | ssj0001507 |
| Score | 2.3323214 |
| Snippet | Evaluate the effect of paliperidone palmitate once-monthly (PP1M) injectable on the specific functioning domains of the Personal and Social Performance (PSP)... Abstract Objective Evaluate the effect of paliperidone palmitate once-monthly (PP1M) injectable on the specific functioning domains of the Personal and Social... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 185 |
| SubjectTerms | Functioning Long term Long-acting injectable Paliperidone palmitate Personal and Social Performance scale Psychiatry Schizoaffective |
| Title | Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0920996417301913 https://www.clinicalkey.es/playcontent/1-s2.0-S0920996417301913 https://dx.doi.org/10.1016/j.schres.2017.04.004 https://www.ncbi.nlm.nih.gov/pubmed/28454922 https://www.proquest.com/docview/1893551055 |
| Volume | 192 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6V9MIFgXiFR7VIXE12_Yr3WFVUAaSqElTqbTX7EkaJHeHkwIV_xn9jZr2OQBQVcYzj8Sae8cy3429mGHstQ4H-UNZZ7kWVlTJ3GTjpM6VsqEMDpnSR5XtRr67K99fV9RE7m2phiFaZfP_o06O3TkcW6W4utm27-CgUlX3WpSQjVTS59jjHaN_M2PHpuw-ri4NDJswTW-7hTokEpgq6SPPCPSTua4njtYw9T9PEthsi1N8QaIxE5_fZvQQh-en4Kx-wI989ZD8uEVBT12LXd55vYb2h4jHPqSoxQ1PbfV5_4xtoO0oFDLyNuYSYGuRtxym6pcwsd_0mntIHjuCQXya0zqFzfCzmpWNTtQEfUMmeT1R2TnldHolepqcrD3tDmZ5h_GKIFD-IHBJ0s9yl3p-P2NX5209nqyyNZshsJetdZsCXAFCYPBcBbFN5KZoyIPyyCBCLoi68V0tjggIBsjGqLCw0xueVs0IYWTxmsw7vx1PGAYwKIVjqhF86t1S5rQxUll6RghFyzopJHdqmvuU0PmOtJ4LaFz0qUZMStSg1KnHOsoPUduzbccv51aRpPdWkohfVGFhukVveJOeH5AoGLfWQa6H_MNdfJX-z-H9Y89VkihqdAb3hgc73e1yroXb5NPN0zp6MNnr494hDqBtf_uy_133O7uKnZuSsv2Cz3de9f4mQbGdO2J033-VJevB-AijCPCI |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZhc2gvpaWv7VOFXs1Ktuy1jyE0bJp0CTSB3ISe1GXXXurdQ35c_ltnZGlpaUpKr7bHsj3j0afRNzOEfOS-AH_Iqyx3rMwEz22mLHdZ0xhf-VppYQPLd1ktrsTn6_L6gBynXBikVUbfP_r04K3jkVn8mrNN286-sgbTPivB0Ugb7Fx7KLCp9YQcHp2eLZZ7h4yYJ5Tcg5USCqQMukDzgjUkrGuR4zUPNU9jx7Y7Zqi_IdAwE508Jo8ihKRH41M-IQeue0puLwBQY9Vi23eObtRqjcljjmJWYgamtv22uqFr1XYYChhoG2IJITRI247i7BYjs9T263BJ7ymAQ3oR0TpVnaVjMi8eS9kGdAAlO5qo7BTjujQQvXSPdx52GiM9w3hiCBQ_FTgk4GapjbU_n5Grk0-Xx4sstmbITMmrbaaVE0qpQuc588rUpeOsFh7glwGAWBRV4Vwz19o3iile60YURtXa5aU1jGlePCeTDr7HS0KV0o333mAlfGHtvMlNqVVpcItUacanpEjqkCbWLcf2GSuZCGrf5ahEiUqUTEhQ4pRke6nNWLfjnuvLpGmZclLBi0qYWO6Rm98l54boCgbJ5ZBLJv8w118lf7P4fxjzQzJFCc4Ad3hU5_odjFVjuXzseTolL0Yb3b894BCsxpe_-u9x35MHi8sv5_L8dHn2mjyEM_XIX39DJtsfO_cW4NlWv4u_30-VWz4I |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Paliperidone+palmitate+once-monthly+maintains+improvement+in+functioning+domains+of+the+Personal+and+Social+Performance+scale+compared+with+placebo+in+subjects+with+schizoaffective+disorder&rft.jtitle=Schizophrenia+research&rft.au=Fu%2C+Dong-Jing&rft.au=Turkoz%2C+Ibrahim&rft.au=Walling%2C+David&rft.au=Lindenmayer%2C+Jean-Pierre&rft.date=2018-02-01&rft.issn=1573-2509&rft.eissn=1573-2509&rft.volume=192&rft.spage=185&rft_id=info:doi/10.1016%2Fj.schres.2017.04.004&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0920-9964&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0920-9964&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0920-9964&client=summon |